Clearmind adds Johns Hopkins site to Phase I/IIa alcohol-use-disorder trial of CMND-100

Clearmind Medicine (CMND) — Clearmind Medicine activated a new clinical site at Johns Hopkins University School of Medicine and enrolled its first participant there in the Phase I/IIa trial of CMND-100, its MEAI-based oral candidate for alcohol use disorder.

The addition followed the enrollment of a first patient at Yale, extending the multinational, multicenter study assessing safety, tolerability, pharmacokinetics and early signals of reduced cravings and consumption. Broadening top-tier US sites is a visibility and execution milestone for the micro-cap.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.